Johnson & Johnson Rated Buy as AI Hedge

Johnson & Johnson offers a defensive portfolio uncorrelated to AI-driven stocks. The company is projected to be the first pharma group to surpass $100 billion in revenue in 2026, supported by 28 platforms generating over $1 billion annually and 13 pharma brands growing double digits. Analysts expect 9% annual returns.